Figure 4
Small molecule MALDI MS fingerprinting enables quantitative comparison of drug responses in K562 cells. (a,c) FT-ICR spectra of Heme B (m/zmeas.: 616.1767, Δm: 0.3 ppm) (a) and PC(36:1) K+ (m/zmeas.: 826.5722, Δm: 0.1 ppm) (c) signals in vehicle control (red) and Imatinib-treated (green) K562 cells. (b,d) Concentration-response curves derived from whole cell MS fingerprints recorded by MALDI-TOF MS enable comparison of EC50 values for different tyrosine kinase inhibitors and control substances. (b) Heme B induction enables monitoring of erythropoiesis in K562 cells. R was used to plot m/z 616.2 feature intensity. (mean ± standard deviation for N = 3 biological replicates prepared on different days). (d) Monitoring of PC(36:1) + K+ enables comparison of different BCR-Abl tyrosine kinase inhibitor potencies. R was used to plot m/z 826.6 feature intensity for different BCR-Abl tyrosine kinase inhibitors (mean ± standard deviation for N = 3 biological replicates prepared on different days).
